--- title: 'Life Sciences Daily Summary: What Happened on November 2, 2026' headline: Povorcitinib meets primary endpoint in two Phase 3 vitiligo trials description: Tezspire improved symptoms in a Phase 3 esophagitis trial, and the FDA approved Ilumya for psoriatic arthritis. url: https://thebench.bio/news/summaries/2026-11-02 topic: all date: '2026-11-02' covers: - '2026-11-02' date_published: '2026-11-02T12:03:19Z' date_modified: '2026-11-02T12:03:19Z' tags: - Clinical - Industry - Regulatory sources: 4 publisher: TheBench.Bio --- # Life Sciences Daily Summary: What Happened on November 2, 2026 **Povorcitinib meets primary endpoint in two Phase 3 vitiligo trials** Tezspire improved symptoms in a Phase 3 esophagitis trial, and the FDA approved Ilumya for psoriatic arthritis. ## Today in brief More patients taking povorcitinib reached the facial repigmentation target than patients on placebo in two Phase 3 vitiligo trials. [1] AstraZeneca and Amgen said Tezspire improved tissue inflammation and swallowing symptoms in a Phase 3 eosinophilic esophagitis trial, with benefits lasting through 52 weeks. [2] The FDA approved Ilumya for adults with active psoriatic arthritis, and Walmart plans to expand its clinical trial centers into three states. [3] Ultragenyx received its first European nod for rare-disease drug Dojolvi. [4] ## Povorcitinib clears the primary endpoint in two vitiligo trials In two placebo-controlled Phase 3 trials, povorcitinib met the week 52 primary endpoint: a higher proportion of treated patients achieved at least 75% improvement in facial Vitiligo Area Scoring Index scores. [1] In STOP-V1, 18.9% of patients taking povorcitinib reached that threshold, compared with 6.8% on placebo. In STOP-V2, the rates were 18.9% and 3.1%. [1] STOP-V1 enrolled 467 patients, and STOP-V2 enrolled 449. The proportion experiencing any treatment-emergent adverse event was similar between drug and placebo groups in both trials. [1] ## Tezspire cuts tissue inflammation and swallowing symptoms in Phase 3 EoE trial In the Phase 3 CROSSING trial in eosinophilic esophagitis, Tezspire improved tissue inflammation and swallowing symptoms, AstraZeneca and Amgen reported. [2] The benefits lasted through 52 weeks. [2] ## FDA approves Ilumya for active psoriatic arthritis The FDA approved Ilumya for adults with active psoriatic arthritis. [3] Walmart is expanding its clinical trial centers into three additional states. [3] ## The day in numbers - **18.9% vs. 6.8%**: STOP-V1 patients on povorcitinib versus placebo who achieved at least 75% improvement in facial vitiligo scores at week 52. [1] - **18.9% vs. 3.1%**: STOP-V2 patients on povorcitinib versus placebo who achieved at least 75% improvement in facial vitiligo scores at week 52. [1] - **52 weeks**: Time through which Tezspire's improvements in the Phase 3 eosinophilic esophagitis trial were sustained. [2] ## Sources 1. [Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials](), Nature Medicine, 2026-11-02 2. [Tezspire improves symptoms and tissue inflammation in phase 3 EoE trial](), Pharmafile, 2026-11-02 3. [ACT Brief: Community Research Policy Needs, Walmart Trial Centers, and Psoriatic Arthritis Approval](), Applied Clinical Trials, 2026-11-02 4. [Ultragenyx gets first Euro nod for rare disease drug Dojolvi](), pharmaphorum, 2026-11-02 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: